Umoja Biopharma, plans for the construction of new manufacturing facility. The new facility will be dedicated for the production of next-generation CAR T immunotherapies.
The state-of-the-art facility designed with 146,000 square foot will overcome the production barriers and delivers effective, accessible cancer treatments.
The new facility features house labs, offices, and manufacturing space for the production of lentiviral vector. In addition, it will further improve the vector manufacturing, process development, and formulation capabilities.
This investment in the new facility is committed to bring new therapies to cancer patients and also will be used for how these therapies are produced, stored, and distributed.
The construction of the manufacturing facility is expected to start its operation in first quarter of 2023.